Clinical Trial Search

Primary: Primary Efficacy Endpoint - Number of Participants With Composite Anatomic and Symptomatic Success at 36 Months — 201; 389; 199; 384 Participants — p=0.056

Primary: Rate of Good Birth Outcomes — 23; 29 Participants — p=0.404

Primary: Percentage of Responders — 80; 87.2; 76.7 percentage of subjects

Primary: Mean Change From Baseline for Mean Reflective Total Nasal Symptom Score (rTNSS) — -2.95; -3.13; -1.98 score on a scale

Primary: Number of Participants With Verified Attendance at Initial Appointment at PrEP Clinic — 30; 13 Participants

Primary: % of Subjects With Successful Preparation Rated by Colonoscopist on a 4 Point Scale (1=Poor to 4 = Excellent) — 13; 10 Participants — p=0.923

Primary: Mean WOMAC Scores at Month 6 — 29; 26 units on a scale

Primary: Rate of Grade 3 or Higher Neutropenia — 10 Participants

Primary: Change From Randomisation to Week 68 in Body Weight (%) — -8.3; 6.5; -8.8; 6.1 Percentage point — p=<0.0001

Primary: Percent of Participants With Clinically Important Change in Drug-induced Liver Injury — 1.0; 0.5; 0 percentage of participants — p== 0.1241

Primary: Emergency Department Arrivals Under 30 Minutes — 5 Participants

Primary: Mineral Loss ΔZ — 235; 774 vol% * μm]

Primary: Correlation Between Cognition Level Changes as Evaluated by Current Clinical Tools (i.e. MMSE) and Brain Activity Features Extracted Using the Neurosteer Technology…

Primary: Number of Days With Bothersome Low Back Pain — 85.2; 98 Number of days with bothersome pain

Primary: Disease Progression as Measured by Serum Levels of Hepatic Enzymes